1 eutic strategy for the clinical treatment of cystinuria.

2 est that 4F2-lc6 is a new candidate gene for cystinuria.

3 ove the diagnosis and clinical management of cystinuria.

4 fective in vivo in a knockout mouse model of cystinuria.

5 ding/trafficking defects that lead to type I cystinuria.

6 ughput, cost-effective diagnostic method for cystinuria, and for point-of-care clinical monitoring.

7  formation in the Slc3a1(-/-) mouse model of cystinuria by increasing the solubility of urinary cysti

8                                          The cystinuria gene SLC7A9 (n=19) was most frequently mutate

9 hree conditions (albinism, alkaptonuria, and cystinuria) have been identified, but the mutations resp

10                                              Cystinuria is an incompletely dominant disorder characte

11                                              Cystinuria is an inherited defect in renal tubular and i

12                                              Cystinuria is discussed relative to mutations in SLC3A1

13                                              Cystinuria is linked to specific mutations in the rBAT s

14                                 Diagnosis of cystinuria is made typically by ion-exchange chromatogra

15                                              Cystinuria is the commonest inherited cause of nephrolit

16 acid transporter that is associated with the cystinuria-related type II membrane glycoprotein, rBAT (

17 studies of patients suffering from hypotonia-cystinuria syndrome (HCS) have revealed a deletion of a